Update Series (2021) Lesson 20: Drug Therapy for Overactive Bladder
At the conclusion of this continuing medical education activity, the participant will be able to:
- Define the unique pharmacokinetic properties of the oral medical therapies for overactive bladder.
- Use the pharmacological properties of anticholinergic and beta-3 agonists to identify potential adverse effects of these medication classes.
- List the upcoming therapeutic options that may be available in the future for the oral treatment of overactive bladder.
Education Council Disclosures
COI Review Work Group Disclosures
Update Series Editorial Committee Disclosures
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
CME CREDITS EXPIRATION:
Please note: CME Credits expire after three years of original release date. Answers must be submitted by the CME credits expiration deadline to receive credit for that year. Refer to CME expiration table below:
|CME Credits Expiration Date|
|2021 Update Series||Month, 2024|
|2020 Update Series||Month, 2023|
|2019 Update Series||Month, 2022|
|2018 Update Series||Month, 2021|
|2017 and prior||Not eligible for CME credits.|
This self-study continuing medical education activity is designed to provide urologists, Board candidates and/or residents affordable and convenient access to the most recent developments and techniques in urology.
METHOD OF PARTICIPATION:
Participants recieve 5 lessons per month for 8 months for a total of 40 lessons. Each lesson is designated for a maximum of 1.0 AMA PRA Category 1 CreditTM. To earn credit, participants must read the educational material provided for each lesson, pass its corresponding online posttest with at least 80% accuracy, submit the online evaluation and claim CME.
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 40.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME enduring material activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction of written materials developed for this AUA activity is prohibited without the written permission from individual authors and the American Urological Association.
Peer review is the principle mechanism by which the quality of the AUA Update Series content is judged by the AUA Update Series Editorial Committee.
Release date: June 2021
Expiration date: June 2024
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation